Nikolaj Kunøe

Nikolaj Kunøe

Auto-generated profile, based on publicly available information

Nikolaj Kunøe

Norwegian Center for Addiction Research, University of Oslo, Oslo, Norway

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
LTLars Tanum
Lars Tanum
KSKristin Klemmetsby Solli
Kristin Klemmetsby Solli
ZLZill-E-Huma Latif
Zill-E-Huma Latif
JBJurate Šaltyte Benth
Jurate Šaltyte Benth
AOArild Opheim
Arild Opheim
NKNikolaj Kunøe
Nikolaj Kunøe
Quiz Ref ID Substance use disorders involving opioids have a higher risk of death, poly drug use, and blood-borne infections, such as HIV and hepatitis, than other substance use disorders.1,2 Owing to the high risk of relapse and overdose in opioid-dependent individuals, the most commonly prescribed treatment is opioid medication treatment (OMT), in which opioids with longer absorption times and half-lives are prescribed, such as the full opioid agonist methadone3 or partial agonist buprenorphine hydrochloride.4 Because of the injection-deterring potential of naloxone hydrochloride and the better safety profile compared with methadone, daily administration of combined buprenorphine and naloxone (buprenorphine-naloxone) is the first choice of OMT medication in a number of countries. However, the extent to which buprenorphine-naloxone deters injection in practice has been debated.5

1 June 2008 in Journal of Analytical Toxicology
Verified
Journal Article
Open access
PDF file
SHS. Hegstad
S. Hegstad
HKH. Z. Khiabani
H. Z. Khiabani
LKL. Kristoffersen
L. Kristoffersen
NKN. Kunoe
N. Kunoe
PLP. P. Lobmaier
P. P. Lobmaier
ACA. S. Christophersen
A. S. Christophersen
Hair has become an important matrix for drug analysis, complementary to blood and urine as a matrix. A prolonged detection window makes hair analysis suitable for lhe detection of exposure to illegal and medicinal drugs for periods up to 12 months. In the present study, a liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for drug screening in hair was developed and validated. To 20 mg of hair, 0.45 mL of acetonitrile/25 mM formic acid (5:95 v/v) and 50 µL of deuterated internal standards were added, and the sample was incubated in a water bath at 37°C for 18 h. LC separation was achieved with a Zorbax SB-Phenyl column (2.1 × 100 mm, 3.5-µm particle). Mass detection was performed by positive ion mode electrospray LC-MS-MS and included the following drugs/metabolites: nicotine, cotinine, morphine, 6-monoacetylmorphine, codeine, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine, cocaine, benzoylecgonine, 7-aminonitrazepam, 7-aminoclonazepam, 7-aminoflunitrazepam, oxazepam, diazepam, alprazolam, zopiclone, zolpidem, carisoprodol, meprobamate, buprenorphine, and methadone. Within- and between-assay relative standard deviations varied from 2.0% to 12% and 2.7% to 15%, respectively. The accuracies were in the range of −24% to 16%, and recoveries ranged from 25% to 100%. The LC-MS-MS method proved to be simple and robust for the determination of drugs in hair. It has been used for authentic samples in our laboratory in the past year.

1 June 2009 in The British Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
NKNikolaj Kunøe
Nikolaj Kunøe
PLPhilipp Lobmaier
Philipp Lobmaier
JVJohn Kåre Vederhus
John Kåre Vederhus
BHBjørg Hjerkinn
Bjørg Hjerkinn
SHSolfrid Hegstad
Solfrid Hegstad
HWHelge Waal
Helge Waal
Background: Naltrexone has considerable potential in helping to prevent relapse in heroin dependency. A longer-lasting formulation for naltrexone treatment is desirable to further reduce non-adherence and relapse during treatment of opiate dependence.Aims: To evaluate the safety and effectiveness of a 6-month naltrexone implant in reducing opioid use after in-patient treatment.Method: A group of 56 abstinence-oriented patients who completed in-patient treatment for opioid dependence were randomly and openly assigned to receive either a 6-month naltrexone implant or their usual aftercare. Drug use and other outcomes were assessed at 6-month follow-up.Results: Patients receiving naltrexone had on average 45 days less heroin use and 60 days less opioid use than controls in the 180-day period (bothP<0.05). Blood tests showed naltrexone levels above 1 ng/ml for the duration of 6 months. Two patients died, neither of whom had received an implant.Conclusions: Naltrexone implant treatment safely and significantly reduces opioid use in a motivated population of patients.

26 April 2010 in European Addiction Research
Verified
Journal Article
Closed access
PDF file
PLPhilipp Paul Lobmaier
Philipp Paul Lobmaier
NKNikolaj Kunøe
Nikolaj Kunøe
MGMichael Gossop
Michael Gossop
TKTormod Katevoll
Tormod Katevoll
HWHelge Waal
Helge Waal
Background:After prison release, offenders with heroin use problems are at high risk of relapse and overdose death. There is a particular need for treatments that can be initiated in prison and continued after release into the community. Methadone maintenance treatment has been shown to reduce heroin use, criminality and mortality. Naltrexone implant treatment has not previously been evaluated in prison settings. Methods:This study compares the effects of naltrexone implants and methadone treatment on heroin and other illicit drug use, and criminality among heroin-dependent inmates after release from prison. Results:Forty-six volunteers were randomly allocated to naltrexone implants or methadone before release. Intention-to-treat analyses showed reductions in both groups in frequency of use of heroin and benzodiazepines, as well as criminality, 6 months after prison release. Conclusions:Naltrexone implants may be a valuable treatment option in prison settings.

23 April 2008 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
PLPhilipp Paul Lobmaier
Philipp Paul Lobmaier
HKH Kornør
H Kornør
NKN Kunøe
N Kunøe
ABA Bjørndal
A Bjørndal

23 September 2010 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
PLPhilipp Paul Lobmaier
Philipp Paul Lobmaier
NKNikolaj Kunøe
Nikolaj Kunøe
MGMichael Gossop
Michael Gossop
HWHelge Waal
Helge Waal